THE-META-DAISIES
2.6.2022 15:02:14 CEST | Business Wire | Press release
In a world first, metaverse rock band The Meta Daisies has released its debut single and meta-cinematic ‘Radiance’, propelling the music industry into a new virtual era. Imagine rock stars from the past being reborn, bringing their music and energy to a new generation - this is The Meta Daisies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220602005548/en/
The Meta Daisies is the digital offspring of The Dead Daisies - a global phenomenon comprised of legends from Deep Purple, Whitesnake and Dio. With their label and management Spitfire Music and a team of metaverse experts, the band built a strategy to bring their music to generations to come. Through The Meta Daisies, the band is building on its legacy while reimagining The Dead Daisies for Gen Z.
The ‘Radiance’ meta-cinematic was made by trailblazing games industry experts Altergaze, creators of HoverGrease and early pioneers in VR & XR. The meta-cinematic gives a glimpse into The Meta Daisies home in the metaverse - Daisyland. Here we meet Daisy, the time travelling, half-human half-supernatural, guardian of The Meta Daisies, who is on a mission to keep rock alive. Check out the meta-cinematic here .
Fans can experience a taste of Daisyland with a listening party in the Avakin Life metaverse from June 9th to June 16th. Metaverse agnostic, The Meta Daisies plan to bring their music to multiple platforms in the future, starting with Avakin Life.
“The metaverse is a new frontier for music, and what better place is there to keep the rock legacy alive?! ” David Edwards, the band’s manager, says. “The Meta Daisies is an exciting new hard-rocking band that is boldly going where no band has gone before. They are bringing everything that we love about rock to a whole new generation, and ‘Radiance’ is just the beginning! We’re really looking forward to the next step of this journey, into Daisyland and the metaverse, bringing new and exclusive music to a new audience of fans. Keep your eyes peeled for more news soon! ”
Behind this project are, David Lowy, The Dead Daisies guitarist and Australian financial magnate, and David Edwards the brains behind Spitfire Music Pty Ltd. They assembled an expert team, including Liviu Antoni of Altergaze (League of Legends, The War of The Worlds) and Dimoso (Marvel, Warner, Angry Birds). Key consultants were also partnered with, including Thomas Lee (Final Fantasy IX) and Kelly Vero (Tomb Raider, Transformers).
To find out more visit www.themetadaisies.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005548/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom